-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Bayer announced that its "first-in-class" therapy Kerendia (finerenone), a phase 3 clinical trial FIGARO-DKD in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) The primary end point was reached
Kerendia is a non-steroidal selective mineralocorticoid receptor antagonist (MRA)
Unlike the previous phase 3 clinical trials, the main patients of FIGARO-DKD have milder symptoms of grade 1-2 CKD (eGFR ≥60 ml/min/1.
▲The primary endpoint data of the FIGARO-DKD clinical trial (picture source: reference [2])
Reference materials:
[1] Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes.